Matthew Perry

601 citations
13 papers · 458 indexed · h-index 8

Matthew Perry

12 papers receiving 434 citations

Peers

Matthew Perry
Comparison fields: 5 of 71
  • Oncology 294
  • Cancer Research 83
  • Hematology 49
  • Pulmonary and Respiratory Medicine 136
  • Epidemiology 103
Replace H. B. Muss with:
H. B. Muss United States
Arzu Yaren Türkiye
Gina Villani United States
B. Melosky Canada
Lee Schwartzberg United States
C. Sessa Switzerland
D Perrault Canada
Simon Meller United Kingdom
Chie Akiba United States
Burton Needles United States
Matthew Perry relative to H. B. Muss United States H. B. Muss's profile →
Citations per field
00.5×1.5×2.2×
H. B. Muss · 1×
Citations per year

Countries citing papers authored by Matthew Perry

Since Specialization
Citations

This map shows the geographic impact of Matthew Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Perry more than expected).

Fields of papers citing papers by Matthew Perry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Perry. The network helps show where Matthew Perry may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew Perry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew Perry Line = papers co-authored together Matthew Perry links everyone, so they are left out of the graph.

All Works

13 of 13 papers shown
#Work
1 20124
2 20100
3 20061
4 20062
5 200290
6
Corticosteroids in advanced cancer.
200145
7 199881
8
Cigarette smoking and adult leukemia. A meta-analysis.
199378
9 199316
10 199329
11 198791
12
Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
19824
13 198117

About Matthew Perry

Matthew Perry is a scholar working on Urology, Oncology and Rheumatology, having authored 13 papers that have together received 458 indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (3 papers), Genital Health and Disease (3 papers), Lung Cancer Research Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Cancer Risks and Factors (2 papers), Urological Disorders and Treatments (2 papers), Urologic and reproductive health conditions (2 papers) and Cancer therapeutics and mechanisms (1 paper). The work is most often cited by research in Oncology (294 citations), Cancer Research (83 citations) and Hematology (49 citations). Matthew Perry has collaborated with scholars based in United States and Canada. Frequent co-authors include James E. Herndon, Thomas E. Novotny, Ross C. Brownson, Walter L. Eaton, James E. Wooldridge, Michael Perloff, Joseph Aisner, Vivian Weinberg, Sandra J. Ginsberg and J F Holland. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, CA A Cancer Journal for Clinicians, JNCI Journal of the National Cancer Institute and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026